Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2000-10-17
2002-10-29
Park, Hankyel T. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S209100, C530S350000, C530S300000
Reexamination Certificate
active
06471964
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a nucleic acid encoding a viral structural protein and the use of the nucleic acid or protein for diagnostic or vaccine purposes.
BACKGROUND OF THE INVENTION
Infectious Salmon Anaemia (ISA) is a disease caused by a virus (ISAV) that belongs to the family Orthomyxoviridae. The disease is characterised by severe anaemia, leucopenia, ascites, haemorrhagic liver necrosis and petecchia of the vicera. The gills are pale, and petecchia of the skin is also common. The spleen is dark and swollen (Speilberg et al, 1995; Veterinary Pathology, 32, pp. 466-478). The virus replicates in endothelial cells, both in blood vessels and in the heart, and in polymorphonuclear leukocytes. Budding of the virus from pillar cells in the gills has been observed, indicating that gills are probably an important portal of entrance for ISAV.
ISA was observed for the first time in Norway (Thorud et al., 1988; Bull. Eur. Ass. Fish Pathol., 8 (5), pp. 109-111) and severe outbreaks have recently been diagnosed also in Scotland, the Shetland Islands and Canada. Mortality during outbreaks varies between 10 and 100% and younger individuals appear to be more susceptible than older individuals. However, high mortality has also been observed among market size fish. Clinical outbreaks have been observed so far in Atlantic salmon, but rainbow trout and brown trout may act as carriers of the agent without developing clinical signs. Despite stamping out strategies, new outbreaks occur regularly and result in significant losses.
SUMMARY OF THE INVENTION
Control of the disease therefore has a high priority, and the present invention provides novel means to carry out such control. The present invention provides for a nucleic acid encoding a structural protein, designated Structural Protein-1 (SP-1) of the ISAV and fragments of said protein. The nucleic acid comprises 1851 nucleotides and is depicted in SEQ ID NO 1; the deduced amino acid sequence of SP-1 is depicted in SEQ ID NO 2. The cloning and characterisation of the nucleic acid according to the invention provides for the production of the SP-1 of the ISAV using recombinant technology (Sambrook et al., Molecular cloning: a Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989). Cloning techniques and subsequent protein expression using in vitro expression systems are well known in the art. In this way, recombinant SP-1 can be obtained, which is substantially free from other ISAV proteins. SP-1 was found to be specific for the ISA virus, which makes this protein very suitable for use in vaccinations and diagnostics. This isolated SP-1 can be used in the manufacture of vaccines to protect fish against infection with ISA virus. The vaccines may be used as marker vaccine to distinguish vaccination from field infections with ISAV. Alternatively, the nucleic acids encoding the SP-1 can be used to manufacture DNA vaccines or vector vaccines to protect fish against infection with ISAV. The nucleic acids and recombinant proteins of the present invention can furthermore be used for diagnostic purposes, for instance, to detect the presence of the ISAV or anti-ISAV antibodies in fish. Additionally, the recombinant SP-1 of the present invention can be used to produce ISAV specific antibodies. These antibodies can also be used for diagnostic purposes such as for detecting of ISAV in fish.
REFERENCES:
patent: 0 839 913 (1998-05-01), None
patent: WO 99 27105 (2000-06-01), None
Jones et al., “Vaccination of Freshwater—reared Atlantic Salmon reduces mortality associated with infectious salmon anaemia virus” Bulletin of the European Associate of Fish Pathologists, vol. 19, No. 3 Jul. 1999, p. 98-101.
Falk et al., “Characterization and applications of a monoclonal antibody against infectious salmon anaemia virus.” Diseases of Aquatic Organisms, vol. 34, No. Oct. 1998, p. 77-85.
Falk et al., “Demonstration of Infectious Salmon Anemia (ISA) Viral-Antigens in Cell-Cultures and Tissue-Sections.” Veterinary Research, col. 26 No. 5-6, 1995, p. 499-504.
Krossoy et al., “The putative polymerase sequence of infectious salmon anemia virus suggests a new genus with the Orthomyxoviridae” Journal of Virology, Mar. 1999, 73 (3) .p. 2136-42.
Falk et al., “Characterization of infectious salmon anemia virus, an orthomyxo-like virus isolated from Atlantic salmon”, Journal of Virology, Dec. 1997, 71 (12) p. 9016-23.
Mjaaland et al., “Genomic characterization of the virus causing infectious salmon anemia in Atlantic salmon: an orthomyxo-like virus in a teleost” Journal of Virology, Oct. 1997, 71 (10) p. 7681-6.
Biering Eirik
Krossøy Bjørn
Akzo Nobel N.V.
Blackstone William M.
Brown Stacy
Milstead Mark W.
Park Hankyel T.
LandOfFree
DNA encoding structural protein-1 of infectious Salmon... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA encoding structural protein-1 of infectious Salmon..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA encoding structural protein-1 of infectious Salmon... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2999245